Published Date:2023-09-25 Original Link:https://www.onenessbio.com/en/news_detail244_2.htm No 1 Date of announcement 2023/09/25 Time of announcement 18:30:26 Subject Oneness has submitted medical device registration application for Bonvadis to the Egyptian Drug Authority (EDA). To which item it meets paragraph 10 Date of events 2023/09/25 Statement 1.Product:Bonvadis for wound care 2.Mass production date:NA 3.Effect on company finances and business:...Read More

Published Date:2023-09-20 Original Link:https://www.onenessbio.com/en/news_detail243_2.htm No 1 Date of announcement 2023/09/20 Time of announcement 16:06:59 Subject Oneness announces the information about the investor’s conference of 2023 Q3 To which item it meets paragraph 12 Date of events 2023/09/27 Statement Date of institutional investor conference:2023/09/27 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online Investor...Read More

Published Date:2023-09-05 Original Link:https://www.onenessbio.com/en/news_detail242_2.htm No 1 Date of announcement 2023/09/05 Time of announcement 16:12:38 Subject The board of directors of the Company approved removal of the noncompete clause for managers. To which item it meets paragraph 21 Date of events 2023/09/05 Statement Date of the board of directors resolution: 2023/09/05 Name and title of the...Read More

Published Date:2023-08-31 Original Link:https://www.onenessbio.com/en/news_detail241_2.htm No 1 Date of announcement 2023/08/31 Time of announcement  21:42:45 Subject Oneness has submitted a 510(k) application to the U.S. FDA to expand the intended patient population and add multiple chronic wound indications for Bonvadis. To which item it meets paragraph 10 Date of events 2023/08/31 Statement Product: Bonvadis for wound...Read More

Published Date:2023-08-15 Original Link:https://www.onenessbio.com/en/news_detail240_2.htm No 1 Date of announcement 2023/08/15 Time of announcement 18:16:56 Subject A Russian patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825 was granted. To which item it meets paragraph 53 Date of events 2023/08/15 Statement Date of occurrence of the event: 2023/08/15 Company name: ONENESS BIOTECH CO., LTD. Relationship to the...Read More

Published Date:2023-08-10 Original Link:https://www.onenessbio.com/en/news_detail239_2.htm No 1 Date of announcement 2023/08/10 Time of announcement  16:23:49 Subject The Company’s 2023 Q2 consolidated financial statements have been approved by the Board of Directors To which item it meets paragraph 31 Date of events 2023/08/10 Statement Date of the board of directors submitted or approved: 2023/08/10 Date of the...Read More

Published Date:2023-08-09 Original Link:https://www.onenessbio.com/en/news_detail238_2.htm No 1 Date of announcement 2023/08/09 Time of announcement  17:49:17 Subject Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in South Africa. To which item it meets paragraph 10 Date of events 2023/08/09 Statement Product: Bonvadis topical cream for wound care Mass production date:...Read More

Published Date:2023-08-04 Original Link:https://www.onenessbio.com/en/news_detail237_2.htm No 1 Date of announcement 2023/08/04 Time of announcement  16:33:35 Subject Oneness was notified today that Bonvadis, the wound care topical cream has submitted a registration application to the Drug Regulatory Authority of Pakistan (DRAP). To which item it meets paragraph 10 Date of events 2023/08/04 Statement Product:Bonvadis topical cream for...Read More

Published Date:2023-08-02 Original Link:https://www.onenessbio.com/en/news_detail236_2.htm No 1 Date of announcement 2023/08/02 Time of announcement 21:48:19 Subject SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai) has been agreed by US FDA to proceed with Phase 2 clinical trial. To which item it meets paragraph 10 Date of events 2023/08/02 Statement Product:SNS812, a...Read More

Published Date:2023-07-20 Original Link:https://www.onenessbio.com/en/news_detail235_2.htm No 1 Date of announcement 2023/07/20 Time of announcement 16:52:07 Subject Oneness Biotech Co., Ltd. receives a European patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2023/07/20 Statement Date of occurrence of the event:2023/07/20 Company...Read More